XML 38 R20.htm IDEA: XBRL DOCUMENT v3.20.2

Revenues (Tables)

6 Months Ended

Jul. 03, 2020

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

Revenues consisted of the following (in thousands):

	Three Months Ended June 30,								Six Months Ended June 30,
	2020				2019				2020				2019
Product revenues:
Gross product revenues	$	229,898			$	240,418			$	482,464			$	464,168
Discounts and allowances	(51,168		)		(46,743		)		(109,854		)		(90,912		)
Net product revenues	178,730				193,675				372,610				373,256
Collaboration revenues:
License revenues	59,234				37,742				80,113				63,306
Collaboration services revenues	21,515				8,858				33,671				19,200
Total collaboration revenues	80,749				46,600				113,784				82,506
Total revenues	$	259,479			$	240,275			$	486,394			$	455,762

Net product revenues by product were as follows (in thousands):

	Three Months Ended June 30,								Six Months Ended June 30,
	2020				2019				2020				2019
CABOMETYX	$	173,610			$	189,015			$	362,826			$	364,905
COMETRIQ	5,120				4,660				9,784				8,351
Net product revenues	$	178,730			$	193,675			$	372,610			$	373,256

The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Ipsen Pharma SAS (Ipsen)	20	%		9	%		17	%		10	%
Affiliates of CVS Health Corporation	13	%		15	%		15	%		15	%
Affiliates of McKesson Corporation	11	%		13	%		13	%		12	%
Affiliates of AmerisourceBergen Corporation	11	%		10	%		11	%		10	%
Affiliates of Optum Specialty Pharmacy	10	%		8	%		11	%		8	%
Takeda Pharmaceutical Company Limited (Takeda)	10	%		1	%		5	%		3	%
Accredo Health, Incorporated	10	%		8	%		9	%		9	%

Revenues by geographic region were as follows (in thousands):

	Three Months Ended June 30,								Six Months Ended June 30,
	2020				2019				2020				2019
U.S.	$	181,231			$	196,347			$	377,827			$	378,473
Europe	52,917				22,249				81,953				44,117
Japan	25,331				21,679				26,614				33,172
Total revenues	$	259,479			$	240,275			$	486,394			$	455,762

Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances

The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):

	Chargebacks and Discounts for Prompt Payment				Other Customer Credits/Fees and Co-pay Assistance				Rebates				Total
Balance at December 31, 2019	$	7,514			$	3,497			$	15,222			$	26,233
Provision related to sales made in:
Current period	72,874				8,339				28,226				109,439
Prior periods	39				(364		)		740				415
Payments and customer credits issued	(72,169		)		(9,111		)		(29,592		)		(110,872		)
Balance at June 30, 2020	$	8,258			$	2,361			$	14,596			$	25,215

X

- Definition

Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]

+ References

No definition available.

+ Details

Name:	exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
Namespace Prefix:	exel_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration